1. Home
  2. HSDT vs OVID Comparison

HSDT vs OVID Comparison

Compare HSDT & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HSDT

Helius Medical Technologies Inc. (DE)

N/A

Current Price

$2.13

Market Cap

77.6M

Sector

Health Care

ML Signal

N/A

Logo Ovid Therapeutics Inc.

OVID

Ovid Therapeutics Inc.

N/A

Current Price

$2.19

Market Cap

117.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HSDT
OVID
Founded
N/A
2014
Country
United States
United States
Employees
21
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
77.6M
117.5M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
HSDT
OVID
Price
$2.13
$2.19
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$3.40
AVG Volume (30 Days)
449.0K
1.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.90
EPS
N/A
N/A
Revenue
N/A
$566,000.00
Revenue This Year
N/A
$1,077.56
Revenue Next Year
$75.13
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$0.24
52 Week High
$25.50
$2.01

Technical Indicators

Market Signals
Indicator
HSDT
OVID
Relative Strength Index (RSI) 46.34 77.34
Support Level $1.78 $1.43
Resistance Level $2.35 N/A
Average True Range (ATR) 0.21 0.13
MACD 0.07 0.07
Stochastic Oscillator 60.16 89.53

Price Performance

Historical Comparison
HSDT
OVID

About HSDT Helius Medical Technologies Inc. (DE)

Solana Co is a publicly listed digital asset treasury established in partnership with Pantera and Summer Capital. The company is dedicated to acquiring Solana (SOL) and aims to maximize SOL per share by strategically leveraging capital market opportunities and on-chain activities. Through this model, Solana Company provides public market investors with efficient and direct exposure to Solana's long-term growth potential.

About OVID Ovid Therapeutics Inc.

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Share on Social Networks: